NH002 (Perflutren Lipid Microspheres) Injectable Suspension

DRUG4 trials

Sponsors

Trust Bio-sonics, Inc., National Taiwan University Hospital

Conditions

Cardiac DiseaseCardiac DiseasesLiver MetastasisPancreatic Adenocarcinoma Metastatic

Phase 1

A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography

CompletedNCT04185246

Trust Bio-sonics, Inc.Cardiac Disease

Start: 2019-11-04End: 2020-07-01Updated: 2025-11-18

NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer

Not yet recruitingNCT07314385

National Taiwan University HospitalLiver Metastasis, Pancreatic Adenocarcinoma Metastatic

Start: 2026-01-01End: 2027-12-31Target: 24Updated: 2026-01-02

Phase 3

Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography

Active, not recruitingNCT06815627

Trust Bio-sonics, Inc.Cardiac Diseases

Start: 2025-03-18End: 2027-02-01Target: 150Updated: 2026-07-09

A Prospective, Multicenter, Phase III Clinical Evaluation of the Safety and Efficacy of NH002 as a Contrast Agent Administrated Via Intravenous Bolus Injection and Infusion for Subjects Undergoing Cardiac Echocardiography

Not yet recruitingNCT07740421

Trust Bio-sonics, Inc.Cardiac Diseases

Start: 2026-07-01End: 2027-07-01Target: 150Updated: 2026-07-31